Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors

Implications for multicenter clinical trials

Keith A. Reimann, Miriam Chernoff, Cynthia L. Wilkening, Christine E. Nickerson, Alan L. Landay, Elizabeth Connick, John L. Fahey, Alan L. Landay, Howard M Lederman, Michael M. Lederman, Norman L. Letvin, M. Juliana McElrath, Richard B. Pollard, T. Fred Valentine

Research output: Contribution to journalArticle

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection results in impaired immune function that can be measured by changes in immunophenotypically defined lymphocyte subsets and other in vitro functional assays. These in vitro assays may also serve as early indicators of efficacy when new therapeutic strategies for HIV-1 infection are being evaluated. However, the use of in vitro assays of immune function in multicenter clinical trials has been hindered by their need to be performed on fresh specimens. We assessed the feasibility of using cryopreserved peripheral blood mononuclear cells (PBMC) for lymphocyte immunophenotyping and for lymphocyte proliferation at nine laboratories. In HIV-1-infected patients with moderate CD4+ lymphocyte loss, the procedures of density gradient isolation, cryopreservation, and thawing of PBMC resulted in significant loss of CD19+ B cells but no measurable loss of total T cells or CD4+ or CD8+ T cells. No significant changes were seen in CD28- CD95+ lymphocytes after cell isolation and cryopreservation. However, small decreases in HLA-DR+ CD38+ lymphocytes and of CD45RA+ CD62L+ were observed within both the CD4+ and CD8+ subsets. Fewer than 10% of those specimens that showed positive PBMC proliferative responses to mitogens or microbial antigens lost their responsiveness after cryopreservation. These results support the feasibility of cryopreserving PBMC for immunophenotyping and functional testing in multicenter AIDS clinical trials. However, small changes in selected lymphocyte subsets that may occur after PBMC isolation and cryopreservation will need to be assessed and considered in the design of each clinical trial.

Original languageEnglish (US)
Pages (from-to)352-359
Number of pages8
JournalClinical and Diagnostic Laboratory Immunology
Volume7
Issue number3
DOIs
StatePublished - May 2000

Fingerprint

Lymphocytes
Viruses
Multicenter Studies
Cryopreservation
HIV-1
Blood Cells
Blood
Tissue Donors
Clinical Trials
Immunophenotyping
Cell Separation
Lymphocyte Subsets
Virus Diseases
Assays
T-cells
T-Lymphocytes
HLA-DR Antigens
Mitogens
Thawing
Acquired Immunodeficiency Syndrome

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Clinical Biochemistry
  • Immunology

Cite this

Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors : Implications for multicenter clinical trials. / Reimann, Keith A.; Chernoff, Miriam; Wilkening, Cynthia L.; Nickerson, Christine E.; Landay, Alan L.; Connick, Elizabeth; Fahey, John L.; Landay, Alan L.; Lederman, Howard M; Lederman, Michael M.; Letvin, Norman L.; McElrath, M. Juliana; Pollard, Richard B.; Valentine, T. Fred.

In: Clinical and Diagnostic Laboratory Immunology, Vol. 7, No. 3, 05.2000, p. 352-359.

Research output: Contribution to journalArticle

Reimann, Keith A. ; Chernoff, Miriam ; Wilkening, Cynthia L. ; Nickerson, Christine E. ; Landay, Alan L. ; Connick, Elizabeth ; Fahey, John L. ; Landay, Alan L. ; Lederman, Howard M ; Lederman, Michael M. ; Letvin, Norman L. ; McElrath, M. Juliana ; Pollard, Richard B. ; Valentine, T. Fred. / Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors : Implications for multicenter clinical trials. In: Clinical and Diagnostic Laboratory Immunology. 2000 ; Vol. 7, No. 3. pp. 352-359.
@article{ddc5842c70a24efe8fc1d00514b6bc3c,
title = "Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: Implications for multicenter clinical trials",
abstract = "Human immunodeficiency virus type 1 (HIV-1) infection results in impaired immune function that can be measured by changes in immunophenotypically defined lymphocyte subsets and other in vitro functional assays. These in vitro assays may also serve as early indicators of efficacy when new therapeutic strategies for HIV-1 infection are being evaluated. However, the use of in vitro assays of immune function in multicenter clinical trials has been hindered by their need to be performed on fresh specimens. We assessed the feasibility of using cryopreserved peripheral blood mononuclear cells (PBMC) for lymphocyte immunophenotyping and for lymphocyte proliferation at nine laboratories. In HIV-1-infected patients with moderate CD4+ lymphocyte loss, the procedures of density gradient isolation, cryopreservation, and thawing of PBMC resulted in significant loss of CD19+ B cells but no measurable loss of total T cells or CD4+ or CD8+ T cells. No significant changes were seen in CD28- CD95+ lymphocytes after cell isolation and cryopreservation. However, small decreases in HLA-DR+ CD38+ lymphocytes and of CD45RA+ CD62L+ were observed within both the CD4+ and CD8+ subsets. Fewer than 10{\%} of those specimens that showed positive PBMC proliferative responses to mitogens or microbial antigens lost their responsiveness after cryopreservation. These results support the feasibility of cryopreserving PBMC for immunophenotyping and functional testing in multicenter AIDS clinical trials. However, small changes in selected lymphocyte subsets that may occur after PBMC isolation and cryopreservation will need to be assessed and considered in the design of each clinical trial.",
author = "Reimann, {Keith A.} and Miriam Chernoff and Wilkening, {Cynthia L.} and Nickerson, {Christine E.} and Landay, {Alan L.} and Elizabeth Connick and Fahey, {John L.} and Landay, {Alan L.} and Lederman, {Howard M} and Lederman, {Michael M.} and Letvin, {Norman L.} and McElrath, {M. Juliana} and Pollard, {Richard B.} and Valentine, {T. Fred}",
year = "2000",
month = "5",
doi = "10.1128/CDLI.7.3.352-359.2000",
language = "English (US)",
volume = "7",
pages = "352--359",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors

T2 - Implications for multicenter clinical trials

AU - Reimann, Keith A.

AU - Chernoff, Miriam

AU - Wilkening, Cynthia L.

AU - Nickerson, Christine E.

AU - Landay, Alan L.

AU - Connick, Elizabeth

AU - Fahey, John L.

AU - Landay, Alan L.

AU - Lederman, Howard M

AU - Lederman, Michael M.

AU - Letvin, Norman L.

AU - McElrath, M. Juliana

AU - Pollard, Richard B.

AU - Valentine, T. Fred

PY - 2000/5

Y1 - 2000/5

N2 - Human immunodeficiency virus type 1 (HIV-1) infection results in impaired immune function that can be measured by changes in immunophenotypically defined lymphocyte subsets and other in vitro functional assays. These in vitro assays may also serve as early indicators of efficacy when new therapeutic strategies for HIV-1 infection are being evaluated. However, the use of in vitro assays of immune function in multicenter clinical trials has been hindered by their need to be performed on fresh specimens. We assessed the feasibility of using cryopreserved peripheral blood mononuclear cells (PBMC) for lymphocyte immunophenotyping and for lymphocyte proliferation at nine laboratories. In HIV-1-infected patients with moderate CD4+ lymphocyte loss, the procedures of density gradient isolation, cryopreservation, and thawing of PBMC resulted in significant loss of CD19+ B cells but no measurable loss of total T cells or CD4+ or CD8+ T cells. No significant changes were seen in CD28- CD95+ lymphocytes after cell isolation and cryopreservation. However, small decreases in HLA-DR+ CD38+ lymphocytes and of CD45RA+ CD62L+ were observed within both the CD4+ and CD8+ subsets. Fewer than 10% of those specimens that showed positive PBMC proliferative responses to mitogens or microbial antigens lost their responsiveness after cryopreservation. These results support the feasibility of cryopreserving PBMC for immunophenotyping and functional testing in multicenter AIDS clinical trials. However, small changes in selected lymphocyte subsets that may occur after PBMC isolation and cryopreservation will need to be assessed and considered in the design of each clinical trial.

AB - Human immunodeficiency virus type 1 (HIV-1) infection results in impaired immune function that can be measured by changes in immunophenotypically defined lymphocyte subsets and other in vitro functional assays. These in vitro assays may also serve as early indicators of efficacy when new therapeutic strategies for HIV-1 infection are being evaluated. However, the use of in vitro assays of immune function in multicenter clinical trials has been hindered by their need to be performed on fresh specimens. We assessed the feasibility of using cryopreserved peripheral blood mononuclear cells (PBMC) for lymphocyte immunophenotyping and for lymphocyte proliferation at nine laboratories. In HIV-1-infected patients with moderate CD4+ lymphocyte loss, the procedures of density gradient isolation, cryopreservation, and thawing of PBMC resulted in significant loss of CD19+ B cells but no measurable loss of total T cells or CD4+ or CD8+ T cells. No significant changes were seen in CD28- CD95+ lymphocytes after cell isolation and cryopreservation. However, small decreases in HLA-DR+ CD38+ lymphocytes and of CD45RA+ CD62L+ were observed within both the CD4+ and CD8+ subsets. Fewer than 10% of those specimens that showed positive PBMC proliferative responses to mitogens or microbial antigens lost their responsiveness after cryopreservation. These results support the feasibility of cryopreserving PBMC for immunophenotyping and functional testing in multicenter AIDS clinical trials. However, small changes in selected lymphocyte subsets that may occur after PBMC isolation and cryopreservation will need to be assessed and considered in the design of each clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=0034062713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034062713&partnerID=8YFLogxK

U2 - 10.1128/CDLI.7.3.352-359.2000

DO - 10.1128/CDLI.7.3.352-359.2000

M3 - Article

VL - 7

SP - 352

EP - 359

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 3

ER -